{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:14:38Z","timestamp":1767914078022,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cpet.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T07:15:46Z","timestamp":1485846946000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Imaging of Prostate Cancer Using 64 Cu-Labeled Prostate-Specific Membrane Antigen Ligand"],"prefix":"10.1016","volume":"12","author":[{"given":"Aviral","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2016.12.001_bib1","unstructured":"Cancer Facts & Figures 2016. American Cancer Society. Available at: http:\/\/www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc-047079.pdf. Accessed September 9, 2016."},{"key":"10.1016\/j.cpet.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.ejca.2013.09.002","article-title":"Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory","volume":"51","author":"Arnold","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2016.12.001_bib3","first-page":"447","article-title":"Imaging of bone metastases in prostate cancer: an update","volume":"56","author":"Langsteger","year":"2012","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib4","first-page":"76","article-title":"The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations","volume":"142","author":"Shinohara","year":"1989","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2431030580","article-title":"Imaging prostate cancer: a multidisciplinary perspective","volume":"243","author":"Hricak","year":"2007","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1148\/rg.313105139","article-title":"Advancements in MR imaging of the prostate: from diagnosis to interventions","volume":"31","author":"Bonekamp","year":"2011","journal-title":"Radiographics"},{"issue":"9","key":"10.1016\/j.cpet.2016.12.001_bib7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00345-015-1749-3","article-title":"Can MRI\/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?","volume":"34","author":"Pepe","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.cpet.2016.12.001_bib8","unstructured":"Available at: http:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed August 8, 2016."},{"issue":"11","key":"10.1016\/j.cpet.2016.12.001_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2967\/jnumed.110.082263","article-title":"SNM practice guideline for sodium 18F-fluoride PET\/CT bone scans 1.0","volume":"51","author":"Segall","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18F-fluoride: applying new technology to an old tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib11","first-page":"287","article-title":"The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT","volume":"47","author":"Even-Sapir","year":"2006","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MOU.0b013e32835483d5","article-title":"Molecular imaging\u00a0of prostate cancer","volume":"22","author":"Fox","year":"2012","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000019923","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy","volume":"36","author":"Hofer","year":"1999","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.cpet.2016.12.001_bib14","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1158\/1078-0432.CCR-04-2034","article-title":"Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy","volume":"11","author":"Morris","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpet.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000070141","article-title":"Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer","volume":"70","author":"Chang","year":"2003","journal-title":"Urol Int"},{"issue":"13","key":"10.1016\/j.cpet.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-05-0249","article-title":"2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy","volume":"11","author":"Sch\u00f6der","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.cpet.2016.12.001_bib17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","article-title":"The fat side of prostate cancer","volume":"1831","author":"Zadra","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"24","key":"10.1016\/j.cpet.2016.12.001_bib18","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1158\/1078-0432.CCR-11-2048","article-title":"Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression","volume":"17","author":"Contractor","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cpet.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.nucmedbio.2004.05.004","article-title":"Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC)","volume":"31","author":"Henriksen","year":"2004","journal-title":"Nucl Med Biol"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2967\/jnumed.107.046672","article-title":"1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer","volume":"49","author":"Vavere","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2967\/jnumed.112.110148","article-title":"Impact of 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics","volume":"54","author":"Beheshti","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1158\/1078-0432.CCR-10-2093","article-title":"The sensitivity of [11C]choline PET\/CT to localize prostate cancer depends on the tumor configuration","volume":"17","author":"Souvatzoglou","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","article-title":"The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis","volume":"64","author":"Umbehr","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.cpet.2016.12.001_bib24","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2967\/jnumed.108.061507","article-title":"Influence of trigger PSA and PSA kinetics on 11C-choline PET\/CT detection rate in patients with biochemical relapse after radical prostatectomy","volume":"50","author":"Castellucci","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7150\/thno.4007","article-title":"Clinical indications of C-choline PET\/CT in prostate cancer patients with biochemical relapse","volume":"2","author":"Picchio","year":"2012","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00259-011-1920-z","article-title":"[11C]choline PET\/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy","volume":"39","author":"Picchio","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2016.12.001_bib27","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2967\/jnumed.110.086074","article-title":"Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer","volume":"52","author":"Okudaira","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib28","first-page":"46","article-title":"A\u00a0preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","author":"Oka","year":"2007","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","article-title":"(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2016.12.001_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/thno.7324","article-title":"Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist \u2013 from mice to men","volume":"4","author":"Wieser","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2016.12.001_bib31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm5012066","article-title":"Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors","volume":"58","author":"Mansi","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cpet.2016.12.001_bib32","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/jm301692p","article-title":"Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, 111In-labeling, and preclinical profile","volume":"56","author":"Marsouvanidis","year":"2013","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cpet.2016.12.001_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7150\/thno.13580","article-title":"In\u00a0vivo stabilization of a gastrin- releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2016.12.001_bib34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","article-title":"Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET\/CT","volume":"43","author":"Maina","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1 \u2013 preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2016.12.001_bib36","first-page":"594","article-title":"The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis","volume":"181","author":"Antunes","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.cpet.2016.12.001_bib38","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2016.12.001_bib39","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/ajcn\/32.4.846","article-title":"The intestinal absorption of folates","volume":"32","author":"Halsted","year":"1979","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cpet.2016.12.001_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(03)12779-1","article-title":"Pathological and molecular aspects of prostate cancer","volume":"361","author":"DeMarzo","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2016.12.001_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-4615-3076-3_4","article-title":"Imaging and dosimetry determinations using radio-labeled antibodies","volume":"68","author":"Carrasquillo","year":"1993","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.cpet.2016.12.001_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00058837","article-title":"Degradation of halogenated aromatic compounds","volume":"1","author":"Commandeur","year":"1990","journal-title":"Biodegradation"},{"key":"10.1016\/j.cpet.2016.12.001_bib43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0090-4295(01)00983-9","article-title":"Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma","volume":"57","author":"Chang","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.cpet.2016.12.001_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.cpet.2016.12.001_bib45","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2016.12.001_bib46","first-page":"303","article-title":"Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng\/mL. BJU","volume":"96","author":"Birtle","year":"2005","journal-title":"Int"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urolonc.2015.05.015","article-title":"State-of-the-art imaging of prostate cancer","volume":"34","author":"Marko","year":"2016","journal-title":"Urol Oncol"},{"issue":"Suppl 10","key":"10.1016\/j.cpet.2016.12.001_bib48","first-page":"S19","article-title":"ProstaScint(R) scan: contemporary use in clinical practice","volume":"6","author":"Taneja","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.cpet.2016.12.001_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/cbr.2000.15.131","article-title":"Capromab pendetide imaging of prostate cancer","volume":"15","author":"Haseman","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.cpet.2016.12.001_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2967\/jnumed.109.067108","article-title":"In\u00a0vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT\/CT","volume":"51","author":"Seo","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2016.12.001_bib51","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-3565(24)37683-9","article-title":"Molecular characterization of human brain N-acetylated \u03b1-linked acidic dipeptidase (NAALADase)","volume":"286","author":"Luthi-Carter","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cpet.2016.12.001_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<28::AID-PROS5>3.0.CO;2-A","article-title":"Characterization of the enzymatic activity of PSM: comparison with brain NAALADase","volume":"39","author":"Tiffany","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.cpet.2016.12.001_bib53","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.cpet.2016.12.001_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1162\/153535002320162750","article-title":"11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase)","volume":"1","author":"Pomper","year":"2002","journal-title":"Mol Imaging"},{"key":"10.1016\/j.cpet.2016.12.001_bib55","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in\u00a0vivo imaging in experimental models of prostate cancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cpet.2016.12.001_bib56","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lutetium-177 PSMA radioligand therapy of metastatic castration resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2016.12.001_bib58","first-page":"1436","article-title":"Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.cpet.2016.12.001_bib59","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.cpet.2016.12.001_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","article-title":"Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer","volume":"4","author":"Weineisen","year":"2014","journal-title":"EJNMMI Res"},{"issue":"Suppl 3","key":"10.1016\/j.cpet.2016.12.001_bib61","first-page":"398","article-title":"The novel PSMA ligand DKFZ-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions","volume":"56","author":"Afshar-oromieh","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2016.12.001_bib62","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib63","first-page":"139","article-title":"PSMA radioligand therapy of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib64","first-page":"1547","article-title":"Response assessment to treatment with Lu-177 PSMA inhibitor in patients with metastatic castration-resistant prostate cancer: differential response of bone versus lymph node lesions","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1367-5931(02)00298-3","article-title":"Molecular mechanisms of copper uptake and distribution","volume":"6","author":"Puig","year":"2002","journal-title":"Curr Opin Chem Biol"},{"issue":"5\u20136","key":"10.1016\/j.cpet.2016.12.001_bib66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2009.07.024","article-title":"Cellular copper management\u2014a draft user\u2019s guide","volume":"254","author":"Bertini","year":"2010","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.cpet.2016.12.001_bib67","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10534-012-9578-y","article-title":"Development of copper based drugs, radiopharmaceuticals and medical materials","volume":"25","author":"Szym\u00e1nski","year":"2012","journal-title":"Biometals"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161207779313768","article-title":"Copper chelation chemistry and its role in copper radiopharmaceuticals","volume":"13","author":"Wadas","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpet.2016.12.001_bib69","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/jm401921j","article-title":"64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"57","author":"Banerjee","year":"2014","journal-title":"J\u00a0Med Chem"},{"issue":"12","key":"10.1016\/j.cpet.2016.12.001_bib70","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-005-1906-9","article-title":"A\u00a0comparison of PET imaging characteristics of various copper radioisotopes","volume":"32","author":"Williams","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0969-8051(96)00157-6","article-title":"Efficient production of high-specific-activity 64Cu using a biomedical cyclotron","volume":"24","author":"McCarthy","year":"1997","journal-title":"Nucl Med Biol"},{"issue":"10","key":"10.1016\/j.cpet.2016.12.001_bib72","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1524\/ract.2011.1821","article-title":"One step purification process for no-carrier-added 64Cu produced using enriched nickel target","volume":"99","author":"Alliot","year":"2011","journal-title":"Radiochim Acta"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0969-8043(93)90172-7","article-title":"Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: possibility of production of No-carrier-added 61Cu and 64Cu at a small cyclotron","volume":"44","author":"Szelecsenyi","year":"1993","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.cpet.2016.12.001_bib74","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/1097-0142(19940201)73:3+<774::AID-CNCR2820731305>3.0.CO;2-L","article-title":"Production of no-carrier-added 64Cu from zinc metal irradiated under boron shielding","volume":"73","author":"Zinn","year":"1994","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2016.12.001_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1524\/ract.1996.75.2.65","article-title":"Separation of 64Cu from 67Ga waste products using anion exchange and low acid aqueous\/organic mixtures","volume":"75","author":"Smith","year":"1996","journal-title":"Radiochimica Acta"},{"key":"10.1016\/j.cpet.2016.12.001_bib76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1524\/ract.2012.1939","article-title":"Preparation of 67Cu via deuteron irradiation of 70Zn","volume":"100","author":"Kozempel","year":"2012","journal-title":"Radiochimica Acta"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.freeradbiomed.2010.10.696","article-title":"A\u00a0copper chelate of thiosemicarbazone NSC 689534 induces oxidative\/ER stress and inhibits tumor growth in\u00a0vitro and in\u00a0vivo","volume":"50","author":"Hancock","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.cpet.2016.12.001_bib78","first-page":"1649","article-title":"PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2","volume":"47","author":"Peng","year":"2006","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2016.12.001_bib79","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11307-015-0908-7","article-title":"Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET\/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer","volume":"18","author":"Nedrow","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.cpet.2016.12.001_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2967\/jnumed.112.107235","article-title":"DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice","volume":"54","author":"M\u00fcller","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2016.12.001_bib81","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1021\/acs.molpharmaceut.6b00143","article-title":"64Cu- and 68Ga-based PET imaging of folate receptor-positive tumors: development and evaluation of an albumin-binding NODAGA-folate","volume":"13","author":"Farkas","year":"2016","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1016\/j.cpet.2016.12.001_bib82","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/cbr.2015.1964","article-title":"64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies","volume":"31","author":"Grubm\u00fcller","year":"2016","journal-title":"Cancer Biother Radiopharm"},{"issue":"Suppl 2","key":"10.1016\/j.cpet.2016.12.001_bib83","first-page":"1538","article-title":"Clinical application of 64Cu PSMA PET\/CT in theranostics of prostate cancer","volume":"57","author":"Singh","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2016.12.001_bib84","first-page":"786463","article-title":"The copper radioisotopes: a systematic review with special interest to 64Cu","volume":"2014","author":"Niccoli","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cpet.2016.12.001_bib85","first-page":"533","article-title":"67Cu- versus 131I-Labeled lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin\u2019s lymphoma","volume":"5","author":"DeNardo","year":"1998","journal-title":"Clin Cancer Res"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859816301353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859816301353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T21:56:00Z","timestamp":1749938160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859816301353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1556859816301353"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2016.12.001","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging of Prostate Cancer Using 64Cu-Labeled Prostate-Specific Membrane Antigen Ligand","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}